Form 10-Q Seres Therapeutics, Inc. For: Jun 30

Go back to Form 10-Q Seres Therapeutics, Inc. For: Jun 30

Seres Therapeutics (MCRB) PT Lowered to $17 at Oppenheimer

August 3, 2018 9:25 AM EDT

Oppenheimer lowered its price target on Seres Therapeutics (NASDAQ: MCRB) to $17.00 (from $18.00) while maintaining a Outperform rating.

... More